Exploring bias in platelet P2Y1 signalling: Host defence versus haemostasis

被引:1
|
作者
Pan, Dingxin [1 ]
Ladds, Graham [2 ]
Rahman, Khondaker Miraz [3 ]
Pitchford, Simon C. [1 ,4 ]
机构
[1] Sackler Inst Pulm Pharmacol, Inst Pharmaceut Sci, Kings Coll London, London, England
[2] Univ Cambridge, Dept Pharmacol, Cambridge, England
[3] Inst Pharmaceut Sci, Kings Coll London, Chem Biol Grp, London, England
[4] Sackler Inst Pulm Pharmacol, Inst Pharmaceut Sci, Kings Coll London, 5-43 Franklin Wilkins Bldg, 150 Stamford St, Water, London SE1 9NH, England
基金
英国医学研究理事会;
关键词
aggregation; biased agonism; chemotaxis; haemostasis; inflammation; P2Y(1); platelets; NEUTROPHIL RECRUITMENT; SHAPE CHANGE; LEUKOCYTE RECRUITMENT; CONCISE GUIDE; MOLECULAR-BASIS; ALPHA-GRANULES; PROTEIN-KINASE; BLEEDING-TIME; ADP RECEPTORS; P-SELECTIN;
D O I
10.1111/bph.16191
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platelets are necessary for maintaining haemostasis. Separately, platelets are important for the propagation of inflammation during the host immune response against infection. The activation of platelets also causes inappropriate inflammation in various disease pathologies, often in the absence of changes to haemostasis. The separate functions of platelets during inflammation compared with haemostasis are therefore varied and this will be reflected in distinct pathways of activation. The activation of platelets by the nucleotide adenosine diphosphate (ADP) acting on P2Y(1) and P2Y(12) receptors is important for the development of platelet thrombi during haemostasis. However, P2Y(1) stimulation of platelets is also important during the inflammatory response and paradoxically in scenarios where no changes to haemostasis and platelet aggregation occur. In these events, Rho-GTPase signalling, rather than the canonical phospholipase C & beta; (PLC & beta;) signalling pathway, is necessary. We describe our current understanding of these differences, reflecting on recent advances in knowledge of P2Y(1) structure, and the possibility of biased agonism occurring from activation via other endogenous nucleotides compared with ADP. Knowledge arising from these different pathways of P2Y(1) stimulation of platelets during inflammation compared with haemostasis may help therapeutic control of platelet function during inflammation or infection, while preserving essential haemostasis.
引用
收藏
页码:580 / 592
页数:13
相关论文
共 50 条
  • [31] Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP- and thrombin-induced human platelet activation
    Nylander, S
    Mattsson, C
    Ramström, S
    Lindahl, TL
    BRITISH JOURNAL OF PHARMACOLOGY, 2004, 142 (08) : 1325 - 1331
  • [32] Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: Role of P2Y1 and P2Y12 receptors.
    Aslam, Muhammad
    Sedding, Daniel
    Koshty, Ahmed
    Santoso, Santot
    Schulz, Rainer
    Hamm, Christian
    Guenduez, Dursun
    THROMBOSIS RESEARCH, 2013, 132 (05) : 548 - 557
  • [33] Key role of the P2Y1 receptor in tissue factor-Induced thrombin-dependent acute thromboembolism -: Studies in P2Y1-knockout mice and mice treated with a P2Y1 antagonist
    Léon, C
    Freund, M
    Ravanat, C
    Baurand, A
    Cazenave, JP
    Gachet, C
    CIRCULATION, 2001, 103 (05) : 718 - 723
  • [34] Loss of P2Y1 receptor desensitization does not impact hemostasis or thrombosis despite increased platelet reactivity in vitro
    Paul, David S.
    Blatt, Tasha N.
    Schug, Wyatt J.
    Clark, Emily G.
    Kawano, Tomohiro
    Mackman, Nigel
    Murcia, Sebastian
    Poe, Kathryn O.
    Mwiza, Jean Marie N.
    Harden, T. Kendall
    Bergmeier, Wolfgang
    Nicholas, Robert A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (07) : 1891 - 1902
  • [35] A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis
    J. Eileen Bird
    Xinkang Wang
    Patricia L. Smith
    Frank Barbera
    Christine Huang
    William A. Schumacher
    Journal of Thrombosis and Thrombolysis, 2012, 34 : 199 - 207
  • [36] P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions
    Maloney, S. F.
    Brass, Lawrence F.
    Diamond, S. L.
    INTEGRATIVE BIOLOGY, 2010, 2 (04) : 183 - 192
  • [37] Discovery of diarylurea P2Y1 antagonists with improved aqueous solubility
    Wang, Tammy C.
    Qia, Jennifer X.
    Clark, Charles G.
    Jua, Ji
    Price, Laura A.
    Wu, Qimin
    Chang, Ming
    Zheng, Joanna
    Huang, Christine S.
    Everlof, Gerry
    Schumacher, William A.
    Wong, Pancras C.
    Seiffert, Dietmar A.
    Stewart, Anne B.
    Bostwick, Jeffrey S.
    Crain, Earl J.
    Watson, Carol A.
    Rehfuss, Robert
    Wexler, Ruth R.
    Lam, Patrick Y. S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3239 - 3243
  • [38] Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor
    Gao, Zhan-Guo
    Jacobson, Kenneth A.
    MOLECULAR PHARMACOLOGY, 2017, 92 (05) : 613 - 626
  • [39] New azole antagonists with high affinity for the P2Y1 receptor
    Ruel, Rejean
    L'Heureux, Alexandre
    Thibeault, Carl
    Daris, Jean-Paul
    Martel, Alain
    Price, Laura A.
    Wu, Qimin
    Hua, Ji
    Wexler, Ruth R.
    Rehfuss, Robert
    Lam, Patrick Y. S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (12) : 3519 - 3522
  • [40] GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12
    Zhao, Xuefei
    Cooper, Matthew
    Michael, James V.
    Yarman, Yanki
    Baltz, Aiden
    Chuprun, J. Kurt
    Koch, Walter J.
    McKenzie, Steven E.
    Tomaiuolo, Maurizio
    Stalker, Timothy J.
    Zhu, Li
    Ma, Peisong
    BLOOD ADVANCES, 2022, 6 (15) : 4524 - 4536